Niacin and Selenium Combination Therapy in Patients With Septic Shock
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 148 people, planned
- Started
- 16 Nov 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Niacin
- Placebo for Niacin
- Selenium
- Placebo for Selenium
- Record updated
- 17 November 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 19 years or older, irrespective of sex or race
- Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:; Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater; Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher; A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered; Written informed consent provided by the participant or an authorized representative; Informed consent and randomization completed within 24 hours after the diagnosis of septic shock
Who cannot take part
- Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit
- Expected death within 72 hours because of the severity of illness
- Known pre-existing liver failure with a Child-Pugh score of 10 or greater
- Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate
- Age younger than 19 years
- Pregnancy or breastfeeding
- Patients for whom aggressive treatment is not being provided in accordance with an advance directive
- Lack of informed consent from the participant or an authorized representative
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.
Read full original descriptionShow less
The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.
Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.
The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.
The 2 groups in the trial
- Niacin plus SeleniumTreatment being tested
Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.
Treatment: Niacin and Selenium
- PlaceboPlacebo, for comparison
Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.
Treatment: Placebo for Niacin and Placebo for Selenium
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combination Therapy of Niacin and Selenium in Patients With Septic Shock (Phase IIa Single Center Double-blind Randomized Controlled Trial)
- Record updated
- 17 November 2026